Lung Cancer Awareness Month
If lung cancer is found at an earlier stage, there is more chance of a better outcome. It’s important to know the symptoms of lung cancer as although lung cancer occurs mostly in people aged 60 and over, it can affect people of any age. New and constantly evolving treatments such as immunotherapy are likely to continue to improve outcomes for people affected by lung cancer. Cancer Australia
Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes British journal of cancer 3 November 2022
Lung screening could be cost-effective in Australia, contingent on translating trial-like lung cancer mortality benefits to the clinic.
Lung cancer: progress with prognosis and the changing state of play MJA 18 April 2022
While tobacco control remains the mainstay of reducing the impact of lung cancer for decades to come, there have been recent highly significant advances in lung cancer diagnostic approaches and treatment regimens which are beginning to affect outcomes for Australians with lung cancer. The adoption of screening for lung cancer will have a further substantial impact, with a stage shift to early, curable disease, and it is likely that the evidence base for many therapeutic approaches described above will move further into the early stage setting. As survival improves for patients with lung cancer, effective strategies in surveillance for recurrence and new primary disease will need to be developed. Further potential for improvements in outcomes for lung cancer can come from the identification and alleviation of the unwarranted, but well documented, variations in the quality of care for patients with lung cancer in Australia.
Investigating suspected lung cancer BMJ 13 July 2022
What you need to know
Advances in systemic therapy for non-small cell lung cancer BMJ 9 November 2021
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.
Prognostic factors for survival in extensive-stage small cell lung cancer: An Italian real-world retrospective analysis of 244 patients treated over the last decade Thoracic cancer 5 November 2022
This data suggest that tumor burden, performance status (PS), and mediastinal radiotherapy (RT) strongly correlate with outcome. With the addition of immunotherapy to chemotherapy (CT), the identification of new biomarkers as predictive factors is urgently required.
Early recurrence factors in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy Thoracic cancer 25 October 2022
A lower tumor proportion score (TPS) may be a predictor of early recurrence after concurrent chemoradiotherapy (CRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC). These patients should be closely monitored for post-treatment recurrence.
Response and safety of whole-brain radiotherapy plus temozolomide for patients with brain metastases of non-small-cell lung cancer: A meta-analysis Thoracic cancer 26 October 2021
Based on the present work, whole-brain radiotherapy plus temozolomide (WBRT+TMZ) can improve the objective response rate (ORR) for brain metastases of non-small-cell lung cancer (NSCLC), but the risk of treatment-associated grade III/IV hematological toxicity and gastrointestinal toxicity were also increased compared to WBRT alone.
Improved trends of lung cancer mortality-to-incidence ratios in countries with high healthcare expenditure Thoracic cancer 7 April 2021
Human development index (HDI), current health expenditure (CHE) per capita, CHE/GDP, and development status play noticeable roles in the prognosis of lung cancer, leading to large disparities in clinical outcomes.
This is just a sample of the journals the library subscribes to – you will need your library login
This is just a sample of the e-books the library subscribes to – you will need your library login